Investors

CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at the International Conference on Opioids, which will be held in Boston on June 5-7, 2016.

Details of the poster presentations are as follows:

Date: Monday, June 6, 2016

Times: 10:00-10:30 am, 12:30-1:30 pm, and 3:30-4:00 pm ET

Location: The Joseph B. Martin Conference Center at Harvard Medical School

Poster #49: “Safety, Tolerability, and Efficacy of Xtampza™ ER (Oxycodone DETERx® extended-release) Treatment in Subjects 65 Years and Older”

Poster #50: “Sprinkle Administration of Xtampza™ ER (Oxycodone DETERx® extended-release): An Abuse-deterrent, Extended-release Formulation”

For more information on the International Conference on Opioids, visit http://www.opioidconference.org/ .

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx^® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

About Xtampza ER

Xtampza™ ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

For Important Safety Information Visit, http://www.xtampzaer.com/

Contact:
Douglas Carlson
Vice President, Corporate Development
dcarlson@collegiumpharma.com